Company: MLTX
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001821586-25-000011
Chunk: 41

Company: MoonLake Immunotherapeutics
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 41
---
 Intrinsic Value (in thousands)Weighted-Average Remaining Contractual Term (in years)Awards outstanding as of January 1, 2025972,476$24.94$28,5888.18Awards granted for the three months ended March 31, 2025229,228$43.11Awards forfeited for the three months ended March 31, 2025(12,891)$49.01Awards outstanding as of March 31, 20251,188,813$28.19$17,1618.28Awards exercisable as of March 31, 2025431,267$13.97$11,3987.27The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period.No options were exercised for the three months ended March 31, 2025.

24

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2025(Unaudited)

Weighted average assumptions for the awards issued during the three months ended March 31, 2025Estimated fair value of the option on the grant date using Black-Scholes model ($)29.64Exercise price ($)43.11Expected term of the award on the grant date (years) (1)6Expected volatility of the share price (2)75%Risk-free interest rate (3)4.4%Expected dividend rate—%(1) The expected term represents the period that share-based awards are expected to be outstanding.(2) The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company’s industry.(3) The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.Weighted average assumptions for the awards issued during the three months ended March 31, 2024Estimated fair value of the option on the grant date using Black-Scholes model ($)36.92Exercise price ($)53.54Expected term of the award on the grant date (years) (1)6Expected volatility of the share price (2)75%Risk-free interest rate (3)4.6%Expected dividend rate—%(1) The expected term represents the period that share-based awards are expected to be outstanding.(2) The expected volatility was derived from the historical stock